
What is claimed is:

1. A compound of Formula IIa:



Formula IIa;

or a pharmaceutically acceptable salt thereof, wherein:

Q is -Cy, -C_{1-4} alkyl-Cy, -CF_3, or C_{1-4} alkyl-CF_3;

R^1 is H;

R^2 is H or C_{1-4} alkyl;

R^4 and R^{4a} are each independently selected from H, halo, and C_{1-4} alkyl;

each R^5 is independently selected from H, halo, and C_{1-4} alkyl, wherein R^5 is attached to a carbon atom;

R^6 and R^7 are each independently selected from H, -OR^a, -NR^cR^d, C_{1-4} alkyl, and C_{1-4} haloalkyl;

Cy is selected from C_{6-10} aryl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 R^{Cy} substituents independently selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, CN, NO_2, OR^a, SR^a, $C(O)R^b$, $C(O)NR^cR^d$, $C(O)OR^a$, $OC(O)R^b$, $OC(O)NR^cR^d$, NR^cR^d, $NR^cC(O)R^b$, $NR^cC(O)OR^a$, $NR^cC(O)NR^cR^d$, $C(=NR^e)R^b$, $C(=NR^e)NR^cR^d$, $NR^cC(=NR^e)NR^cR^d$, $NR^cS(O)R^b$, $NR^cS(O)_2R^b$, $NR^cS(O)_2NR^cR^d$, $S(O)R^b$, $S(O)NR^cR^d$, $S(O)_2R^b$, and $S(O)_2NR^cR^d$;

or two adjacent R^{Cy} substituents together with the atoms to which they are attached form a fused phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, CN, NO_2, OR^a, SR^a, $C(O)R^b$, $C(O)NR^cR^d$, $C(O)OR^a$, $OC(O)R^b$, $OC(O)NR^cR^d$, NR^cR^d, $NR^cC(O)R^b$, $NR^cC(O)OR^a$, $NR^cC(O)NR^cR^d$, $C(=NR^e)R^b$, $C(=NR^e)NR^cR^d$, $NR^cC(=NR^e)NR^cR^d$, $NR^cS(O)R^b$, $NR^cS(O)_2R^b$, $NR^cS(O)_2NR^cR^d$, $S(O)R^b$, $S(O)NR^cR^d$, $S(O)_2R^b$, and $S(O)_2NR^cR^d$;

each R^a, R^b, R^c, and R^d is independently selected from H, C_{1-4} alkyl, and C_{1-4} haloalkyl, wherein said C_{1-4} alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

each R^e is independently selected from H, C_{1-4} alkyl, and CN;

n is 0, 1, or 2; and

m is 1 or 2.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^2 is H;

R^4 is H; and

R^{4a} is H.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein:

R^6 and R^7 are each independently selected from H and OH.

4. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein:

at least one of R^6 and R^7 is H;

both R^6 and R^7 are H; or

R^6 is OH and R^7 is H.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein:

Q is $-CF_3$.


6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein:

Q is –Cy;

Cy is thiazoyl optionally substituted by 1 or 2 R^{Cy} substituents; and

each R^{Cy} substituent is independently selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, CN, OR^a, $C(O)R^b$, $C(O)NR^cR^d$, $C(O)OR^a$, NR^cR^d, $NR^cC(O)R^b$, $NR^cS(O)_2R^b$, $S(O)_2R^b$, and $S(O)_2NR^cR^d$.

7. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein

Cy is 

.

8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein

n is 0; and

m is 1.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is a compound selected from:

4-((2-(2,2,2-Trifluoroethyl)-1*H*-imidazol-4-yl)methyl)pyridine;

4-((2-(3,3,3-trifluoropropyl)-1H-imidazol-4-yl)methyl)pyridine;

2-(4-(Pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)acetonitrile;

3-(4-(Pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)propanenitrile;

rac-4-(1-(2-(2,2,2-Trifluoroethyl)-1*H*-imidazol-4-yl)ethyl)pyridine;

(R)-4-(1-(2-(2,2,2-Trifluoroethyl)-1*H*-imidazol-4-yl)ethyl)pyridine;

(S)-4-(1-(2-(2,2,2-Trifluoroethyl)-1*H*-imidazol-4-yl)ethyl)pyridine;

5-((4-(Pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)methyl)thiazole;

4-((5-(2,2,2-Trifluoroethyl)-1*H*-1,2,4-triazol-3-yl)methyl)pyridine;

2-(Pyridin-4-ylmethyl)-4-(2,2,2-trifluoroethyl)thiazole;

4-(Pyridin-4-ylmethyl)-2-(2,2,2-trifluoroethyl)thiazole;

rac-4-(1-(5-(2,2,2-trifluoroethyl)-1*H*-pyrrol-2-yl)ethyl)pyridine;

(*S*)-2,2,2-Trifluoro-1-(5-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)ethan-1-ol;

(*R*)-2,2,2-Trifluoro-1-(5-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)ethan-1-ol;

2,2,2-Trifluoro-1-(5-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)ethan-1-one;

(*E*/*Z*)-2,2,2-Trifluoro-1-(5-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)ethan-1-one oxime;

4-((5-Methyl-2-(2,2,2-trifluoroethyl)-1*H*-imidazol-4-yl)methyl)pyridine;

(*S*)-2,2,2-trifluoro-1-(4-(pyridin-4-ylmethyl)-1H-imidazol-2-yl)ethan-1-amine;

(*R*)-2,2,2-trifluoro-1-(4-(pyridin-4-ylmethyl)-1H-imidazol-2-yl)ethan-1-amine;

(*S*)-2,2,2-Trifluoro-*N*-methyl-1-(5-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)ethan-1-amine;

(*R*)-2,2,2-Trifluoro-*N*-methyl-1-(5-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)ethan-1-amine;

(*S*)-2,2,2-Trifluoro-*N*,*N*-dimethyl-1-(5-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)ethan-1-amine;

(*R*)-2,2,2-Trifluoro-*N*,*N*-dimethyl-1-(5-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)ethan-1-amine;

(*E*/*Z*)-2, 2, 2-Trifluoro-1-(4-(pyridin-4-ylmethyl)thiazol-2-yl) ethan-1-one oxime;

(*R*)-2,2,2-Trifluoro-1-(5-(pyridin-4-ylmethyl)thiazol-2-yl)ethan-1-amine;

(*S*)-2,2,2-Trifluoro-1-(5-(pyridin-4-ylmethyl)thiazol-2-yl)ethan-1-amine;

(*S*)-(4-(Pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)(thiazol-5-yl)methanol;

(*R*)-(4-(Pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)(thiazol-5-yl)methanol;

(5-((3-Methylpyridin-4-yl)methyl)-1*H*-imidazol-2-yl)(thiazol-5-yl)methanol;

3,5-Dichloro-4-((2-(2,2,2-trifluoroethyl)-1*H*-imidazol-5-yl)methyl)pyridine;

1-(4-((3-Chloropyridin-4-yl)methyl)-1*H*-imidazol-2-yl)-2,2,2-trifluoroethan-1-ol;

(*S*)-2,2,2-trifluoro-1-(4-((*S*)-1-(pyridin-4-yl)ethyl)-1*H*-imidazol-2-yl)ethan-1-ol;

(*R*)-2,2,2-trifluoro-1-(4-((*S*)-1-(pyridin-4-yl)ethyl)-1*H*-imidazol-2-yl)ethan-1-ol;

(*S*)-2,2,2-trifluoro-1-(4-((*R*)-1-(pyridin-4-yl)ethyl)-1*H*-imidazol-2-yl)ethan-1-ol;

(*R*)-2,2,2-trifluoro-1-(4-((*R*)-1-(pyridin-4-yl)ethyl)-1*H*-imidazol-2-yl)ethan-1-ol;

3-Methyl-4-((2-(2,2,2-trifluoroethyl)-1*H*-imidazol-4-yl)methyl)pyridine;

(*R*)-2,2,2-Trifluoro-1-(4-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)-1-(thiazol-5-yl)ethan-1-ol; and

(*S*)-2,2,2-Trifluoro-1-(4-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)-1-(thiazol-5-yl)ethan-1-ol;

3-Chloro-4-((2-(2,2,2-trifluoroethyl)-1*H*-imidazol-4-yl)methyl)pyridine;

2-Chloro-4-((2-(2,2,2-trifluoroethyl)-1*H*-imidazol-4-yl)methyl)pyridine;

2-Fluoro-4-((2-(2,2,2-trifluoroethyl)-3*H*-imidazol-4-yl)methyl)pyridine;

(*S*)-(5-((3-Methylpyridin-4-yl)methyl)-1*H*-imidazol-2-yl)(thiazol-5-yl)methanol;

(*R*)-(5-((3-Methylpyridin-4-yl)methyl)-1*H*-imidazol-2-yl)(thiazol-5-yl)methanol;

(*R*)-(5-(Pyridin-4-ylmethyl)-1H-imidazol-2-yl)(thiazol-2-yl)methanol;

(*S*)-(5-(Pyridin-4-ylmethyl)-1H-imidazol-2-yl)(thiazol-2-yl)methanol;

(*R*)-1,1,1-Trifluoro-2-(5-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)propan-2-ol;

(*S*)-1,1,1-Trifluoro-2-(5-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)propan-2-ol;

(*S*)-4-((2-(2,2,2-trifluoro-1-methoxyethyl)-1*H*-imidazol-5-yl)methyl)pyridine;

(*R*)-4-((2-(2,2,2-trifluoro-1-methoxyethyl)-1*H*-imidazol-5-yl)methyl)pyridine;

(*R*)-2,2,2-Trifluoro-1-(5-((2-fluoropyridin-4-yl)methyl)-1*H*-imidazol-2-yl)ethan-1-ol;

(*S*)-2,2,2-Trifluoro-1-(5-((2-fluoropyridin-4-yl)methyl)-1*H*-imidazol-2-yl)ethan-1-ol;

Pyridin-2-yl(5-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)methanol;

3-Fluoro-4-((2-(2,2,2-trifluoroethyl)-1H-imidazol-4-yl)methyl)pyridine;

(*S*)-2,2,2-Trifluoro-1-(4-((3-methylpyridin-4-yl)methyl)-1*H*-imidazol-2-yl)ethan-1-ol;

(*R*)-2,2,2-Trifluoro-1-(4-((3-methylpyridin-4-yl)methyl)-1*H*-imidazol-2-yl)ethan-1-ol;

(*S*)-2,2,2-Trifluoro-1-(4-((3-fluoropyridin-4-yl)methyl)-1*H*-imidazol-2-yl)ethan-1-ol;


(*R*)-2,2,2-Trifluoro-1-(4-((3-fluoropyridin-4-yl)methyl)-1*H*-imidazol-2-yl)ethan-1-ol;

1,1,1,3,3,3-Hexafluoro-2-(4-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)propan-2-ol; and

1,1,1-Trifluoro-2-(4-(pyridin-4-ylmethyl)-1*H*-imidazol-2-yl)propan-2-ol;


or a pharmaceutically acceptable salt of any of the aforementioned.

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:




or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:




or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:




or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:



or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:



or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising

at least one pharmaceutically acceptable carrier; and

a compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof.

16. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof for use in therapy.

17. Use of a compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a neurological disorder in a patient in need thereof.